Clinical Trials
MediPearl is planning to have a phase I dose finding clinical trial of Proveq MPCB in breast cancer patients with refractory tumours at the National Cancer Center. MediPearl is also arranging to continue a randomized phase III study of Proveq MPCB in the recurrence of patients with metastasis breast cancer who have achieved a major response with first or second line chemotherapy at National Cancer Center, when the phase I study is completed.
|
4/6 |
 |
 |
